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Abstract
Background: Early diagnosis of HIV infection can prevent morbidity and mortality as well as reduce HIV
transmission. The aim of the present study was to assess prevalence, describe trends and identify factors associated
with late presentation of HIV infection in Barcelona (Spain) during the period 2001-09.
Methods: Demographic and epidemiological characteristics of cases reported to the Barcelona HIV surveillance
system were analysed. Late presentation was defined for individuals with a CD4 count below 350 cells/ml upon
HIV diagnosis or diagnosis of AIDS within 3 months of HIV diagnosis. Multivariate logistic regression were used to
identify predictors of late presentation.
Results: Of the 2,938 newly diagnosed HIV-infected individuals, 2,507 (85,3%) had either a CD4 cell count or an
AIDS diagnosis available. A total of 1,139 (55.6%) of the 2,507 studied cases over these nine years were late
presenters varying from 48% among men who have sex with men to 70% among heterosexual men. The
proportion of late presentation was 62.7% in 2001-2003, 51.9% in 2004-2005, 52.6% in 2006-2007 and 52.1% in
2008-2009. A decrease over time only was observed between 2001-2003 and 2004-2005 (p = 0.001) but remained
constant thereafter (p = 0.9). Independent risk factors for late presentation were older age at diagnosis (p <
0.0001), use of injected drugs by men (p < 0.0001), being a heterosexual men (p < 0.0001), and being born in
South America (p < 0.0001) or sub-Saharan Africa (p = 0.002).
Conclusion: Late presentation of HIV is still too frequent in all transmission groups in spite of a strong
commitment with HIV prevention in our city. It is necessary to develop interventions that increase HIV testing and
facilitate earlier entry into HIV care.
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Introduction
In the European Union it is estimated that 15-38% of
cases of HIV infection are diagnosed late [1] and 30% of
infected individuals are not aware of their serological
status, with proportions that vary between 12% and 20%
in Sweden to more than 50% in Poland [2]. In Spain
56.3% of new diagnoses of HIV infection between 2003
and 2007 required treatment (CD4 < 350 cells/μl) at the
time of diagnosis and 30.2% of these presented severe
immunosuppression (CD4 < 200 cells/μl) [3].
Reducing the time elapsed between infection and the
initiation of antiretroviral therapy (ART) is important to
decrease progression of the infection and to facilitate
immunological recovery. Therefore, early identification
of infected individuals has been a priority of most AIDS
prevention and control programs since the beginning of
AIDS epidemic [4-6].
Delays in HIV care have serious public health implica-
tions because opportunities to prevent further transmis-
sion through effective ART are lost [7,8], and because
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initiating treatment for HIV infection at an advanced
stage leads to poorer treatment outcomes than with
early treatment [9,10]. Also, some studies have shown
that after HIV infection diagnosis, most infected indivi-
duals remain sexually active, although most use safer
practices, thereby limiting infection spread [11-13]. Late
diagnosis of HIV also has economic implications for
health services and society [14-16].
In Spain, all citizens enjoy universal free access to
health services and ART is available for all patients.
Delayed diagnosis and access to ART is essentially a
public health problem and a loss of opportunity to limit
the progression of disease and reduce the transmission
of infection. For this reason, the objective of the present
study was to determine the frequency of individuals pre-
senting for care with a CD4 count below 350 cells/μl or
presenting with an AIDS-defining event, to evaluate
trends in this proportion, and to identify factors asso-
ciated with late presentation of HIV infection in Barce-
lona during the period 2001-09.
Methods
The city of Barcelona (1.6 million inhabitants), is located
in the northern part of the east coast of Spain. In 2001,
11.89 AIDS cases and 17.47 cases of HIV infections
were registered per 100,000 inhabitants. This figures
decreased to 5.9 AIDS cases and 16.7 HIV infections in
2009. The Barcelona AIDS Surveillance System, which
has been active since 1987, is an active system that col-
lects data provided by doctors, hospital discharges, the
tuberculosis (TB) register, and mortality databases
regarding patients diagnosed with AIDS. The voluntary
HIV Surveillance System, which has been active since
2001, collects information about new diagnoses of HIV
infection in individuals older than 13 years tested in
public or private facilities. All AIDS cases were collected
through Barcelona AIDS Surveillance, and all HIV cases
from the voluntary HIV Surveillance system.
Clinicians complete a standard data collection form
and use a unique patient identifier code [17].
In this study, we considered all new diagnoses of HIV
infection or of AIDS within 3 months of a positive HIV
test among individuals older than 13 years who were
resident in Barcelona during the period 2001-09. These
cases of AIDS and HIV infection met the relevant cri-
teria of the European Centre for AIDS/HIV Epidemiolo-
gical Surveillance[18].
We analysed demographic data (sex, date and country
of birth, year of arrival in Spain), HIV exposure category
(injecting drug users [IDU], sex between men [MSM],
heterosexuals [HT]), calendar period of HIV diagnosis
(subdivided into 4 periods: 2001-03, 2004-05, 2006-07
and 2008-09), clinical data (AIDS, absolute CD4+ [CD4]).
According to the new European definition[19], late
presenters (LP) was defined for persons presenting for
care with a CD4 count below 350 cells/μl or presenting
with an AIDS-defining event at the time of HIV diagno-
sis or within 3 months of the HIV-positive test, regard-
less of the CD4 cell count. Other patients were
classified as non-late presenters.
Statistical analyses
A descriptive analysis of the epidemiological characteris-
tics of cases of HIV infection defined as late presenters
was carried out.
For categorical and continuous variables, we compared
the count (proportion) and median (interquartile range
-IQR-), respectively, of late presenters to non late pre-
senters. Categorical variables were compared using c2
test. For each comparison, the univariate odds ratio
(OR), 95% confidence interval (CI) and p-value for sta-
tistical significance were computed. Continuous vari-
ables were compared using the Mann-Whitney U test or
the Kruskal-Wallis test. Trends in LP over time were
analysed using the c2 test for trend in proportions. Mul-
tivariate logistic regression was used to identify predic-
tors of late presentation. A p-value of < 0.05 was
considered to be statistically significant. Statistical ana-
lyses were performed using SPSS for Windows (Version
18.0; SPSS, Chicago, IL).
All data were collected by the HIV/AIDS Registry of
Barcelona City and were handled in a strictly confiden-
tial manner according to the requirements of Spanish
data protection Law[20].
Results
During the study period, 2,938 new cases of HIV infec-
tion were detected, of which 2,268 (76.2%) were
detected in hospital and 670 (22.8%) in non-hospital set-
tings. The majority of cases were male (83.3%), with a
median age of 35 years, MSM (51.8%) and 19.9% pre-
sented with AIDS. The most common AIDS-defining
conditions were TB (26.2%), Pneumocystis jirovecii
pneumonia (24.3%) and Kaposi Sarcoma (10.3%). In 90%
of cases the AIDS diagnosis was made within 30-days of
HIV infection. We observed that the proportion of IDU
among males decreased during the study period (p <
0.0001), whereas the proportion of MSM increased from
40.2% in 2001-03 to 61.9% in 2008-09 (p < 0.0001).
However, no significant trend was observed in IDU and
HT women (p = 0.1 y p = 0.2, respectively) (Table 1).
55% of cases were born in Spain. The proportion of
migrants increased from 22.6% in 2001-03 to 45.8% in
2008-09 (p < 0.0001), of which 37.8% had been resident
in Spain for less than 1 year, 38.8% between 2 and 5
years and 8.3% more than 10 years.
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Either a CD4 cell count or an AIDS diagnosis were
available for 85.3% (2,507) of the 2,938 newly diagnosed
HIV-infected individuals. Patients whose CD4 cell count
was not available differed from those for whom CD4
count was available in the frequency of IDU (26.0% vs
12.9%, p < 0.001) and in the median age (34.43 years vs
37.39 years, p < 0.001).
The proportion of patients who were LP was 55.6%
(1,393 persons) and 38.5% had advanced HIV infection
(15.2% presenting with CD4 < 200 cell//μl and 23.3%
with AIDS regardless of the CD4 cell count). A decrease
of LP over time only was observed from 62.7% in 2001-
03 to 51,9% in 2004-05 (p = 0.001), but remained con-
stant thereafter (p = 0.9). Figure 1 shows the proportion
of individual by CD4 count/AIDS at the time of HIV
diagnosis according to category of exposure: 48% of
MSM had < 350 CD4/μl, whereas among IDU men and
HT men this percentage was 66% and 70%, respectively.
LP was slightly, but not significantly, more frequent
among women than among men (58.5% vs 55.0%). How-
ever, differences were observed according to age, region
of birth, category of exposure and period of diagnosis
(Table 2). The logistic regression model showed that
risk of LP was associated with age: for each increment
of 5 years, risk of being a late presenter increased by
38%; with region of birth: LP was significantly more
common among individuals born in Latin America and
Caribbean (OR:1.48; CI: 1.20-1.83) and Sub-Saharan
Africa (OR:2.43; CI: 1.14-4.17) than among individuals
born in Spain; with category of exposure and sex: IDU
and HT men showed an OR for risk of being LP of 2.12
(1.57-2.87) and 1.79 (1.38-2.34), respectively, compared
Table 1 Characteristics of newly diagnosed HIV-infected patients in Barcelona (Spain), 2001-2009
Characteristics 2001-2003;n = 956
(100%)
2004-2005;n = 630
(100%)
2006-2007;n = 691
(100%)
2008-2009; n = 661
(100%)
Total; N = 2938
(100%)
Sex
Male 768 (80.3) 502 (79.7) 599 (86.7) 581 (87.9) 2450 (83.4)
Female 188 (19.3) 128 (20.3) 92 (13.3) 80 (12.1) 488 (16.6)
Age at HIV diagnosis*
All 35.1 (29.8-42.9) 34.7 (28.9-41.7) 35.5 (29.9-43.1) 34.3 (29.2-41.1) 35.0 (29.4-42.2)
Male 35.2 (29.8-42.8) 34.8 (29.3-41.6) 35.5 (29.8-42.7) 34.2 (29.0-40.8) 35.1 (29.5-35.1)
Female 34.5 (29.8-42.9) 36.7 (27.4-42.1) 35.9 (30.0-44.9) 35.3 (29.3-44.8) 34.5 (29.3-43.4)
Region of birth
Spain 551 (57.6) 353 (56.0) 368 (53.3) 344 (52.0) 1616 (55.0)
Western Europe & North
America
53 (5.5) 30 (4.8) 53 (7.7) 54 (8.2) 190 (6.5)
Latin America & Caribbean 147 (15.4) 133 (21.1) 191 (27.6) 178 (26.9) 649 (22.1)
Middle East & North Africa 22 (2.3) 7 (1.1) 12(1.7) 9(1.4) 50(1.7)
Sub-Saharan Africa 30 (3.1) 33 (5.2) 20 (2.9) 20 (3.0) 103 (3.5)
Eastern Europe 14 (1.5) 12 (1.9) 20 (2.9) 36 (5.4) 82 (2.8)
Asia 6 (0.6) 6 (1.0) 1 (0.1) 6 (0.9) 19 (0.6)
unknown 133 (13.9) 56 (8.9) 26 (3.8) 14 (2.1) 229 (7.8)
Exposure category by
sex**
IDU men 181 (18.9) 65 (10.3) 52 (7.5) 29 (4.4) 327 (11.1)
MSM 384 (40.2) 320 (50.8) 410 (59.3) 409 (61.9) 1523 (51.8)
HT men 149 (15.6) 85 (13.5) 93 (13.5) 87 (13.2) 414 (14.1)
IDU women 48 (5.0) 22 (3.5) 10 (1.4) 12 (1.8) 92 (3.1)
HT women 129 (13.5) 102 (16.2) 74 (10.7) 54 (8.2) 359 (12.2)
unknown 65 (6.8) 36 (5.7) 52 (7.5) 70 (10.6) 223 (7.6)
CD4 cell count and AIDS
AIDS 241 (25.2) 105 (16.7) 138 (20.0) 100 (15.1) 584 (19.9)
< 200 141 (14.7) 78 (12.4) 81 (11.7) 74 (11.2) 374 (12.7)
200-349 123 (12.9) 96 (15,2) 100 (14,5) 116 (17.5) 435 (14.8)
350-499 111 (11,6) 92 (14.6) 117 (16.9) 108 (16.3) 428 (14.6)
500 and more 189 (19.8) 167 (26.5) 171 (24.7) 159 (24.1) 686 (23.3)
unknown (%) 151 (15.8) 92 (14.6) 84 (12.2) 104 (15.7) 431 (14.7)
*Median (interquartile range). **IDU: injection drug use; MSM: men who have sex with men; HT: heterosexual contact.
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to MSM. A decrease in the risk of being LP was
observed in the last three periods compared to the per-
iod 2001-03 (Table 2).
In 650 (33.8%) cases of the 1,923 new diagnoses of
HIV infection with CD4 count data and without AIDS
the median time elapsed between the diagnosis of infec-
tion and the first determination of CD4 was 56 days
(15-129), with differences according to category of expo-
sure. Among IDU, the median time interval was 162
days (40-495), while for other exposures it was 54 days
(14-115) (p = 0,002).
Discussion
This study shows that a high proportion of individuals
(55.6%) meet the criteria of the new European definition
of LP (CD4 < 350 cells/μl or AIDS). Although it is diffi-
cult to obtain data on LP in large cities, these figures do
not differ greatly from those observed at national or
regional level, even in areas where the prevention of
HIV infection is a priority [1,3,21,22]. Thus, 50% of new
diagnoses of HIV infection occur when the subject
needs treatment [23]. If we take into account the new
ARV treatment recommendations, which indicate that
treatment should be started in asymptomatic patients
with CD4 < 500 cells/μl, this proportion reaches 70%
[24-26]. These high proportions of patients with “care-
stage” HIV infection at their initial clinic visit suggests
that barriers to HIV care are also considerable in devel-
oped countries. The negative impact of LP is a likely
increase in morbidity and mortality [27,28], more poten-
tial transmission at the community level [13] and further
treatment costs [14-16].
The proportion of LP decreased only between 2001-03
and 2004-05, as has been observed in other studies
[3,29], it continues to be high in all groups. LP is asso-
ciated with age and affects all subpopulations, although
its distribution is not homogeneous [3,30]. The limited
perception of risk [31] compounds the fact that tests
tend to be offered less frequently to older individuals.
Heterosexual individuals over 50 years are not the target
of most prevention campaigns [32]. In general, indivi-
duals born outside Spain presented greater risk of LP
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Total
MSM
HTm
HTw
IDUm
IDUw
Figure 1 Proportion of individual by CD4 count/AIDS at the time of HIV diagnosis according to sex and category of exposure in
Barcelona (Spain): 2001-2009. IDUw: injection drug use women; IDUm: injection drug use men; HTw: heterosexual women; HTm: heterosexual
men; MSM: men who have sex with men.
de Olalla et al. AIDS Research and Therapy 2011, 8:22
http://www.aidsrestherapy.com/content/8/1/22
Page 4 of 7
than Spanish nationals, most notably individuals born in
Latin America and Sub-Saharan Africa, as observed in
other studies [3,10]. In a study carried out in Italy, a
greater proportion of LP was also observed in the immi-
grant population [29].
In relation to sex and the mechanism of transmission,
it was observed that IDU men and HT men presented a
higher frequency of LP compared to MSM. This higher
proportion of delayed diagnoses among heterosexuals
compared to cases of homosexual transmission has been
highlighted in various studies [33-35]. A greater prob-
ability of delayed diagnosis has been observed in Italy,
but only in drug addicts that remained isolated from
social and health services [36]. However in our study,
comparing the MSM group with IDU women or HT
women this difference disappears. This may be due to
women’s higher perception of risk, their greater likeli-
hood of attending health services [37] and the probabil-
ity that they will be offered the test during pregnancy or
birth, as a result of which they will be diagnosed earlier
than HT or IDU men.
Some results of this study suggest that the delay
among IDU is more a delay in beginning treatment than
in diagnosis of the infection, since they are often diag-
nosed in drug rehabilitation centres or in prison. In this
sense, the overrepresentation of IDU without lympho-
cyte count data would indicate that the diagnostic test is
carried out on these individuals, but many are lost to
follow-up. Moreover, the median time elapsed between
the diagnosis of infection and the determination of CD4
was notably higher among the IDU (162 days) compared
to other categories of exposure (54 days), which would
indicate that the delay in this group was more likely due
to a delay in beginning treatment than delayed diagno-
sis, as observed in other studies [38,39]. Consequently,
public health strategies aimed at ensuring access to
health resources are a priority for diminishing LP in this
group. An early diagnosis, especially in this group does
Table 2 Characteristics and factors associated with late presentation for newly HIV diagnosis in Barcelona (Spain),
2001-2009
Characteristics Total N = 2507 Late presenters (%) Unadjusted OR (CI) p value Adjusted OR (CI) p value
Sex
Male 2097 1153 (55.0) 1 0.18
Female 410 240 (58.5) 1.16 (0.93-1.44)
Age at HIV diagnosis*
All 35.4 (29.6-42.8) 37.9 (31.5-46.2) 0.0001 1.38 (1.27-1.40) <0.0001
Male 35.4 (29.7-42.5) 38.0 (31.8-45.8)
Female 35.3 (29.4-44.4) 37.7 (30.6-47.2)
Age (per a 5 yrs increase)
Region of birth
Spain 1460 826 (56.6) 1 0.002 1 0.279
Western Europe & North America 166 73 (44.0) 0.60 (0.43-0.84) 0.2 0.83 (0.59-1.16) < 0.0001
Latin America & Caribbean 570 315 (55.3) 0.95 (0.78-1.16) 0.8 1.48 (1.20-1.83) 0.838
Middle East & North Africa 44 26 (59.1) 1.11 (0.58-2.13) 0.02 1.07 (0.56-2.03) 0.002
Sub-Saharan Africa 74 52 (70.3) 1.81 (1.08-3.12) 0.9 2.43 (1.14-4.17) 0.274
Eastern Europe 64 36 (56.3) 0.99 (0.58-1.68) 0.2 1.35 (0.79-2.31) 0.219
Asia 18 13 (72.2) 2.00 (0.66-6.44) 0.05 1.96 (0.67-5.74) 0.107
unknown 111 52 (46.8) 0.68 (0.45-1.01) 0.71 (0.47-1.07)
Exposure category**
MSM 1333 636 (47.7) 1 < 0.001 1 < 0.0001
IDU men 252 166 (65.9) 2.12 (1.58-2.83) < 0.001 2.12 (1.57-2.87) < 0.0001
HT men 382 269 (70.4) 2.61 (2.03-3.36) 0.9 1.79 (1.38-2.34) 0.340
IDU women 62 34 (54.8) 1.33 (0.78-2.29) 0.004 1.29 (0.76-2.20) 0.279
HT women 319 181 (56.7) 1.44 (1.12-1.85) < 0.001 1.16 (0.88-1.51) 0.009
unknown 159 107 (67.3) 2.26 (1.57-3.24) 1.63 (1.13-2.37)
Year of diagnosis
2001-2003 805 505 (62.7) 1 < 0.001 1 0.001
2004-2005 538 279 (51.2) 0.64 (0.51-0.80) < 0.001 0.67 (0.53-0.85) 0.001
2006-2007 607 319 (52.6) 0.66 (0.53-0.82) < 0.001 0.67 (0.53-0.85) 0.001
2008-2009 557 290 (52.1) 0.65 (0.52-0.81) 0.71 (0.56-0.90)
*Median (interquartile range). **IDU: injection drug use; MSM:men who have sex with men; HT:heterosexual contact.
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not necessarily require that the patient be undergoing
follow-up or treatment [40,41]. However, reinforcing the
strategies that increase the availability of the test should
be directed in the first place at those individuals likely
to be at high risk for HIV infection based on the pre-
sence of indicator situations or events where the esti-
mated prevalence of HIV-1 infection is above 1%, and at
the most vulnerable groups [42-44].
Among the limitations of this study, we highlight the
number of cases without data on lymphocyte count
(14.7%) with a different distribution in the case of the
IDU, which may lead to underestimation of the results
for this group in our study. Another limitation could be
the under-reporting of HIV infection due to the fact
that this was voluntary. This underreporting is estimated
around 15%-20% (unpublished data).
Conclusion
In conclusion, late presentation of HIV is common in
spite of a strong commitment to universal access to
HIV infection prevention, diagnosis and treatment in
our city. This study reveals a need to develop interven-
tions that increase HIV testing and facilitate earlier
entry into care, such as routine screening in healthcare
and non-clinical settings for patients at risk for HIV (e.
g. have unprotected sex with many sex partners, have a
sexually transmitted infection, have a diagnosis of tuber-
culosis, use illegal injected drugs, pregnancy). An accu-
rate sexual history and other risk factors, together with
knowledge of country of birth, can identify most indivi-
duals who should be offered an HIV test and a link to
care.
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